EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to a combination of Lactobacillus helveticus CNCM I-1722 and Bifidobacterium longum subsp. Longum CNCM I-3470 and alleviation of psychological stress (ID 938) and “maintains the balance of healthy microbiota that helps to strengthen the natural defence” (ID 2942) (further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 by 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 20, 2017
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on
the substantiation of health claims related to a combination of Lactobacillus helveticus
CNCM I-1722 and Bifidobacterium longum subsp. Longum CNCM I-3470 and alleviation
of psychological stress (ID 938) and “maintains the balance of healthy microbiota that
helps to strengthen the natural defence” (ID 2942) (further assessment) pursuant to
Article 13(1) of Regulation (EC) No 1924/2006
EFSA Publication; Tetens, Inge
Link to article, DOI:
10.2903/j.efsa.2012.2849
Publication date:
2012
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
EFSA Publication (2012). EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on
the substantiation of health claims related to a combination of Lactobacillus helveticus CNCM I-1722 and
Bifidobacterium longum subsp. Longum CNCM I-3470 and alleviation of psychological stress (ID 938) and
“maintains the balance of healthy microbiota that helps to strengthen the natural defence” (ID 2942) (further
assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. Parma, Italy: European Food Safety
Authority.  (The EFSA Journal; No. 2849, Vol. 10(8)). DOI: 10.2903/j.efsa.2012.2849
  EFSA Journal 2012;10(8):2849 
 
Suggested citation: EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the 
substantiation of health claims related to a combination of Lactobacillus helveticus CNCM I-1722 and Bifidobacterium 
longum subsp. Longum CNCM I-3470 and alleviation of psychological stress (ID 938) and “maintains the balance of healthy 
microbiota that helps to strengthen the natural defence” (ID 2942) (further assessment) pursuant to Article 13(1) of 
Regulation (EC) No 1924/2006. EFSA Journal 2012;10(8):2849. [18 pp.]. doi:10.2903/j.efsa.2012.2849. Available online: 
www.efsa.europa.eu/efsajournal 
 
© European Food Safety Authority, 2012 
SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to a 
combination of Lactobacillus helveticus CNCM I-1722 and Bifidobacterium 
longum subsp. longum CNCM I-3470 and alleviation of psychological stress 
(ID 938) and “maintains the balance of healthy microbiota that helps to 
strengthen the natural defence” (ID 2942) (further assessment) pursuant to 
Article 13(1) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies 
(NDA) was asked to provide a scientific opinion on health claims pursuant to Article 13 of Regulation (EC) No 
1924/2006 in the framework of further assessment related to a combination of Lactobacillus helveticus CNCM 
I-1722 and Bifidobacterium longum subsp. longum CNCM I-3470 and alleviation of psychological stress and 
“maintains the balance of healthy microbiota that helps to strengthen the natural defence”. The food constituent 
that is the subject of the health claims, a combination of L. helveticus CNCM I-1722 and B. longum subsp. 
longum CNCM I-3470, is sufficiently characterised. The claimed effect, alleviation of psychological stress, is a 
beneficial physiological effect. No human intervention studies were provided from which conclusions could be 
drawn for the scientific substantiation of the claim. On the basis of the data provided, the Panel concludes that a 
cause and effect relationship has not been established between the consumption of a combination of L. helveticus 
CNCM I-1722 and B. longum subsp. longum CNCM I-3470 and alleviation of psychological stress. From the 
information provided for the claimed effect “maintains the balance of healthy microbiota that helps to strengthen 
the natural defence” it was not possible to establish the specific effect which is the subject of the claim. The 
Panel considers that the claimed effect is general and non-specific, and does not refer to any specific health claim 
as required by Regulation (EC) No 1924/2006. © European Food Safety Authority, 2012 
KEY WORDS 
Lactobacillus helveticus CNCM I-1722, Bifidobacterium longum subsp. longum CNCM I-3470, psychological 
stress, microbiota, natural defence, health claims.
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SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to provide a scientific opinion on a list of health claims pursuant to 
Article 13 of Regulation (EC) No 1924/2006. The Commission has agreed with EU Member States 
that a certain number of Article 13 health claims would be eligible for further assessment by EFSA in 
order to be able to take a final decision on whether or not to include these claims in the list of 
permitted health claims. This opinion addresses the scientific substantiation of health claims in 
relation to the combination of Lactobacillus helveticus CNCM I-1722 and Bifidobacterium longum 
subsp. longum CNCM I-3470 and alleviation of psychological stress and “maintains the balance of 
healthy microbiota that helps to strengthen the natural defence”. The scientific substantiation is based 
on the information provided by the competent Authorities of the United Kingdom and of Italy for 
further assessment of this claim. 
The food constituent that is the subject of the health claims is a combination of L. helveticus CNCM 
I-1722 and B. longum subsp. longum CNCM I-3470. The Panel considers that the combination of 
L. helveticus CNCM I-1722 and B. longum subsp. longum CNCM I-3470 is sufficiently characterised. 
Alleviation of psychological stress 
The claimed effect, which is proposed for further assessment, is “significant improvement of stress-
induced psychological and gastrointestinal symptoms like anxiety, anger-hostility, depressive 
symptoms, nausea and abdominal pain”. The proposed target population is healthy adults 
experiencing moderate stress or anxiety. The Panel considers that alleviation of psychological stress is 
a beneficial physiological effect. 
One double-blind, placebo-controlled, randomised, parallel study assessed the effect of a combination 
of L. helveticus CNCM I-1722 and B. longum CNCM I-3470 on symptoms claimed to be related to 
stress. Symptoms were assessed by a self-administered questionnaire at the beginning and at the end 
of the intervention. The Panel notes that no information was given about validation of the 
questionnaire used for subjective measurements, that the process of randomisation was insufficiently 
described, that inclusion criteria (at least two symptoms perceived as induced by stress) were not 
sufficiently defined, and that no correction for multiple testing was performed in the statistical 
analysis of the results. The Panel considers that no conclusions can be drawn from this study for the 
scientific substantiation of the claim.  
Another double-blind, placebo-controlled, randomised, parallel study, which was described in two 
publications, assessed the potential anxiolytic effect of a combination of L. helveticus CNCM I-1722 
and B. longum CNCM I-3470. The Panel notes that this study was designed for measuring anxiety and 
not changes induced by stress, and considers that no conclusions can be drawn from this study for the 
scientific substantiation of the claim.  
No human intervention studies were provided from which conclusions could be drawn for the 
scientific substantiation of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of a combination of L. helveticus CNCM I-1722 and 
B. longum subsp. longum CNCM I-3470 and alleviation of psychological stress. 
“Maintains the balance of healthy microbiota that helps to strengthen the natural defence” 
The claimed effect, which is proposed for further assessment, is “maintains the balance of healthy 
microbiota that helps to strengthen the natural defence”. The proposed target population is the general 
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population. The Panel notes that from the information provided it was not possible to establish the 
specific effect which is the subject of the claim. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
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INTRODUCTION 
The Commission has agreed with EU Member States that a certain number of Article 13 health claims 
would be eligible for further assessment by EFSA in order to be able to take a final decision on 
whether or not to include these claims in the list of permitted health claims. These claims include 
already assessed claims related to micro-organisms which the Panel considered to be not sufficiently 
characterised and claims for which the NDA Panel concluded that there was insufficient evidence to 
establish a cause and effect relationship between the consumption of the food and the claimed effect. 
Following an opinion of the NDA Panel pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 in 
which the Panel concluded that the data available were not sufficient to characterise a combination of 
Lactobacillus helveticus CNCM I-1722 and Bifidobacterium longum CNCM I-3470 and a 
combination of Lactobacillus acidophilus Bar 13 (CNCM-I-3857) and Bifidobacterium longum 
Bar 33 (CNCM-I-3858) (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2009, 
2010), EFSA received additional information from the competent Authorities of the United Kingdom 
and of Italy for further assessment of this claim. The information provided in the framework of further 
assessment for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
1. Characterisation of the food/constituent  
The food constituent that is the subject of the health claims is a combination of Lactobacillus 
helveticus CNCM I-1722 and Bifidobacterium longum subsp. longum CNCM I-3470.  
According to the information provided in the application for further assessment of ID 2942, the food 
constituent which is the subject of ID 2942 is a combination of L. helveticus R0052 and B. longum 
R0175. L. helveticus R0052 is also known as L. helveticus CNCM I-1722, and B. longum R0175 is 
also known as B. longum CNCM I-3470. 
Data on the identification and characterisation of L. helveticus CNCM I-1722 at species and strain 
level, by using both phenotypic (cell morphology, colony morphology, carbohydrate fermentation 
pattern, enzymatic activity profile, antimicrobial resistance pattern, PAGE) and genotypic 
(DNA-DNA hybridisation, 16S rRNA gene sequence analysis, 16S/23S intergenic spacer region 
sequence analysis, species-specific PCR, AFLP, MLST, RAPD, PFGE) methods, were provided in the 
applications for further assessment and in the accompanying references (Brigidi, 2008; Firmesse et 
al., 2008; Kheadr, 2006; Lallemand SAS; Naser et al., 2006). The Panel considers that the strain 
L. helveticus CNCM I-1722 is sufficiently characterised. 
Data on the identification and characterisation of B. longum subsp. longum CNCM I-3470 at species 
and strain level, by using both phenotypic (cell morphology, colony morphology, carbohydrate 
fermentation pattern, enzymatic activity profile, antimicrobial resistance pattern) and genotypic (16S 
rRNA gene sequence analysis, elongation factor tuf gene sequence analysis, RAPD, PFGE) methods, 
were provided in the application for further assessment and in the accompanying references (Brigidi, 
2008; Kheadr et al., 2007; Lallemand SAS; Mattarelli et al., 2008). The Panel considers that the strain 
B. longum subsp. longum CNCM I-3470 is sufficiently characterised. 
The Panel considers that the food constituent, a combination of L. helveticus CNCM I-1722 and 
B. longum subsp. longum CNCM I-3470, which is the subject of the health claims, is sufficiently 
characterised. 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
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2. Relevance of the claimed effect to human health  
2.1. Alleviation of psychological stress (ID 938) 
The claimed effect, which is proposed for further assessment, is “significant improvement of stress-
induced psychological and gastrointestinal symptoms like anxiety, anger-hostility, depressive 
symptoms, nausea and abdominal pain”. The proposed target population is healthy adults 
experiencing moderate stress or anxiety. 
The Panel assumes that the claimed effect refers to alleviation of psychological stress. The Panel 
considers that alleviation of psychological stress is a beneficial physiological effect. 
2.2. “Maintains the balance of healthy microbiota that helps to strengthen the natural 
defence” (ID 2942) 
The claimed effect, which is proposed for further assessment, is “maintains the balance of healthy 
microbiota that helps to strengthen the natural defence”. The proposed target population is the general 
population. 
The Panel notes that it is not possible to define the exact number of the different microbial groups 
which constitute a balanced healthy microbiota.  
The references provided in relation to this claim included reports on identification and 
characterisation aspects of the bacterial strains (Naser et al., 2006), a review on anti-inflammatory 
activity of different bacterial strains (Mengheri, 2008), an in vitro study on the properties of the 
bacterial strains (i.e. adhesion, competition against enteropathogens and modulation of IL-8 
production (Candela et al., 2008)), an animal study investigating the effect of the combination of the 
strains which is the subject of the claim on an experimental model of induced colitis in mice (Roselli 
et al., 2009), and a human intervention study investigating the effect of a combination of the strains 
containing also fructo-oligosaccharides on the composition of gut microbiota and metabolic profiles 
(Vitali et al., 2010). An abstract from a meeting was also provided; the abstract reported on a human 
study conducted with the combination of the strains that is the subject of the claim on lymphocyte 
subsets from elderly subjects (Finamore, 2011). The Panel notes that from the information provided it 
was not possible to establish the specific effect which is the subject of the claim. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006.  
3. Scientific substantiation of the claimed effect  
3.1. Alleviation of psychological stress (ID 938) 
Among the references provided in relation to the claim were human, animal and in vitro studies which 
were unrelated to the combination of L. helveticus CNCM I-1722 and B. longum CNCM I-3470 
(Estrada et al., 2001; Firmesse et al., 2008; Haskey and Dahl, 2006; Johnson-Henry et al., 2007; Wine 
et al., 2009). The Panel considers that no conclusions can be drawn from these studies for the 
scientific substantiation of the claim. 
Three human intervention studies on a combination of L. helveticus CNCM I-1722 and B. longum 
CNCM I-3470 (Diop et al., 2008; Messaoudi et al., 2010; 2011) were provided for the scientific 
substantiation of the claim. 
Health claims related to a combination of L. helveticus CNCM I-1722 
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Diop et al. (2008) in a double-blind, placebo-controlled, randomised, parallel study assessed the effect 
of a combination of L. helveticus CNCM I-1722 and B. longum CNCM I-3470 on symptoms claimed 
to be related to stress. Adult volunteers aged 18-60 years with at least two symptoms (anxiety, 
nervousness, irritability, sleeping problems, gastro-intestinal disturbances) perceived as induced by 
stress during the preceding month, but not receiving any medical treatment for stress-induced 
symptoms, were eligible for the study. Subjects randomly received a combination of the two bacterial 
strains (3 x 10
9 
CFU per sachet, L. helveticus CNCM I-1722 and B. longum CNCM I-3470 in a ratio 
of 9:1, one sachet daily) or placebo for three weeks. Participants completed a questionnaire on stress-
induced symptoms at the beginning and at the end of the intervention. The questionnaire consisted of 
62 items related to symptoms in the following areas: gastro-intestinal, cardiovascular, sleeping, 
locomotor, physical, psychological, intellectual, spiritual and social. Each symptom was evaluated 
using a 10-cm visual analogue scale (VAS). A global score for each area was determined as the mean 
of each item. The changes of the score between the baseline and the end of the study were calculated 
and compared between the two groups using the unpaired Student’s t test. A total of 75 subjects (54 
females, aged 38±11 years) were randomised (37 in the study group and 38 in the placebo group) and 
64 finished the study (31 in the intervention group and 33 in the placebo group). The reasons for drop-
outs were given. The Panel notes that no information was given about the validation of the 
questionnaire used for subjective measurements, that the process of randomisation was insufficiently 
described, that inclusion criteria (at least two symptoms perceived as induced by stress) were not 
sufficiently defined and justified, and that no correction for multiple testing was performed in the 
statistical analysis of the results. The Panel considers that no conclusions can be drawn from this 
study for the scientific substantiation of the claim.  
Messaoudi et al. (2010) studied the potential anxiolytic effect of a combination of L. helveticus 
CNCM I-1722 and B. longum CNCM I-3470 in a double-blind, placebo-controlled, randomised, 
parallel study. The Hospital Anxiety and Depression Scale (HADS) was used for the enrolment of 
subjects. Their results had to be ≤20 in the HADS total score, ≤12 in HADS-anxiety subscale and ≤12 
in HADS-depression subscale. Sixty-six subjects were randomised to take either the combination of 
bacterial strains which is the subject of the claim (in the form of sticks, 3 x 10
9 
CFU daily, 
L. helveticus CNCM I-1722 and B. longum CNCM I-3470 content in a ratio of 90:10) or placebo, 
identical in taste and appearance, for 30 days. Fifty-five subjects finished the study (26 subjects in the 
intervention group, 29 subjects in the control group, mean age 42.4 years in the intervention group 
and 43.2 years in the control group). At the beginning and at the end of the intervention the 
participants completed a set of questionnaires: the Hopkins Symptom Checklist (HSCL-90), the 
HADS, the Perceived Stress Scale (PSS) and the coping checklist (CCL). Moreover, 24 h urinary free 
cortisol was measured. In a separate publication (Messaoudi et al., 2011), a secondary sub-group 
analysis of the results of the above-described study for 25 subjects (10 in the study group and 15 in 
the control group) with urinary free cortisol concentrations less than 50 ng/ml at baseline was 
presented. The Panel notes that this study was designed for measuring anxiety and not changes 
induced by stress. The Panel considers that no conclusions can be drawn from these studies for the 
scientific substantiation of the claim.  
The submitted studies in animals evaluated the results of administration of the combination of 
bacterial strains which is the subject of the claim on the conditioned defensive burying test 
(Messaoudi et al., 2010), on depressive behaviour after experimental myocardial infarction 
(Arseneault-Breard et al., 2011), and on apoptosis in the limbic system after myocardial infarction 
(Girard et al., 2009). The in vitro studies measured the effect of the combination of bacterial strains 
which is the subject of the claim on the proliferation rate of splenocytes and on immunoglobuline 
production (Easo et al., 2002), their survival in simulated gastro-intestinal conditions (Possemiers et 
al., 2010), the susceptibility of several bacterial strains affected by chemical stress to different 
antibiotics (Kheadr, 2006; Kheadr et al., 2007), and the effect of various Lactobacillus and 
Bifidobacterium strains on cytokine production by human intestinal epithelial cells (Wallace et al., 
2003). The Panel considers that in the absence of evidence for an effect on the alleviation of 
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psychological stress in humans, evidence provided in these animal and in vitro studies cannot be used 
for the scientific substantiation of a claim on alleviation of psychological stress. 
The Panel notes that no human intervention studies were provided from which conclusions could be 
drawn for the scientific substantiation of the claim. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of a combination of L. helveticus CNCM I-1722 and B. longum subsp. longum CNCM 
I-3470 and alleviation of psychological stress. 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent, a combination of L. helveticus CNCM I-1722 and B. longum CNCM 
I-3470, which is the subject of the health claims, is sufficiently characterised. 
Alleviation of psychological stress (ID 938) 
 The claimed effect proposed for further assessment is “significant improvement of stress-
induced psychological and gastrointestinal symptoms like anxiety, anger-hostility, depressive 
symptoms, nausea and abdominal pain”. The proposed target population is healthy adults 
experiencing moderate stress or anxiety. Alleviation of psychological stress is a beneficial 
physiological effect. 
 A cause and effect relationship has not been established between the consumption of a 
combination of L. helveticus CNCM I-1722 and B. longum subsp. longum CNCM I-3470 and 
alleviation of psychological stress. 
“Maintains the balance of healthy microbiota that helps to strengthen the natural defence” 
(ID 2942) 
 The claimed effect proposed for further assessment is “maintains the balance of healthy 
microbiota that helps to strengthen the natural defence”. The proposed target population is the 
general population. The claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006.  
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 for further assessment 
(No: EFSA-Q-2012-00130, EFSA-Q-2012-00178). The scientific substantiation is based on the 
information provided by the competent Authorities of the United Kingdom and of Italy for further 
assessment of this claim (available at: http://www.efsa.europa.eu/en/topics/topic/article13.htm). 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
5
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
6
  
Foods are commonly involved in many different functions
7
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent.  
                                                     
5  OJ L12, 18/01/2007 
6  The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
7  The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).   
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
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 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Health claims related to a combination of Lactobacillus helveticus CNCM I-1722 and 
Bifidobacterium longum subsp. longum CNCM I-3470, including conditions of use, as proposed in the 
framework of further assessment. 
ID Food or Food constituent Health Relationship Proposed wording 
938 A combination of 2 bacterial 
strains: Lactobacillus 
helveticus CNCM I-1722 and 
Bifidobacterium longum 
subsp. Longum CNCM I-
3470. 
The percentage of each strain 
is respectively 90% and 10%, 
under the form of lyophilised 
microencapsulated powders. 
The finished product is 
commercialised as a stick 
sachet under the brand name 
Probio’Stick®. 
Significant improvement of 
stress-induced psychological 
and gastrointestinal 
symptoms like anxiety, 
anger-hostility, depressive 
symptoms, nausea and 
abdominal pain. 
The improvement of some of the 
psychological and 
gastrointestinal disorders linked 
to stress. 
Conditions of use 
It is recommended to take 3*10
9
 CFU of the food constituent per day. 
Healthy adults experiencing moderate stress or anxiety is the target population. 
ID Food or Food constituent Health Relationship Proposed wording 
2942 Lactobacillus 
acidophilus/helveticus Bar 13 
(CNCM-I-3857) and 
Bifidobacterium longum Bar 
33 (CNCM-I-3858) - mix 1:1  
Maintains the balance of 
healthy microbiota, that 
helps to strengthen the 
natural defence  
Maintains the balance of healthy 
microbiota, that helps to 
strengthen the natural defence  
Conditions of use 
The clinical trial in healthy people with a daily intake of 1 Alixir Immunitas chocolate bar 
demonstrated the adhesion to the intestinal epithelium cells of the strains Bar 13 and Bar33 and 
an increase of Bifidobacteria in healthy people who had naturally low level of Bifidobacteria  
1 serving per day, containing 10
9
 CFU of probiotics Bar13 and Bar33/serving The serving 
corresponds to 1 bar ALIXIR IMMUNITAS weighting 16g and delivering 80 kcal  
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GLOSSARY AND ABBREVIATIONS 
AFLP  Amplified fragment length polymorphism 
CCL  Coping checklist 
CNCM  Collection Nationale de Cultures de Microorganismes, France 
DNA  Deoxyribonucleic acid  
HADS  Hospital anxiety and depression scale  
HSCL  Hopkins symptom checklist  
MLST  Multi-locus sequence typing 
PAGE  Polyacrylamide gel electrophoresis 
PCR  Polymerase chain reaction 
PFGE  Pulsed field gel electrophoresis 
PSS  Perceived stress scale 
RAPD  Random amplification of polymorphic DNA 
RNA  Ribonucleic acid  
VAS  Visual analogue scale 
